Monday, October 26, 2026

Credit Markets

2 articles

Oxford Lane Capital Corp. Stakes 97% of Income on Riskiest CLO Tranche Amid Credit Cycle Concerns

Oxford Lane Capital Corp. Stakes 97% of Income on Riskiest CLO Tranche Amid Credit Cycle Concerns

Oxford Lane Capital Corp. derives $114.3M of its $117.8M investment income—97%—from CLO equity tranches, the most junior position in collateralized loan obligations. The concentration exposes the closed-end fund to severe losses if the credit cycle deteriorates, as equity holders absorb first losses when underlying leveraged loans default.

ViaNews Editorial Team (Markets)•
UK Property-Backed Securities Face Liquidity Test as Keyzy Holds £147M Backlog

UK Property-Backed Securities Face Liquidity Test as Keyzy Holds £147M Backlog

Keyzy, a UK proptech lender using asset-backed funding for property purchases, holds £147M in backlog amid rising credit market repricing risk. The company's funding model faces vulnerability as interest rates remain elevated and liquidity conditions tighten for UK property-backed securities. Market analysts assess the refinancing risk as medium likelihood but potentially catastrophic if capital markets reprice risk or liquidity evaporates.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com